Endonovo Therapeutics, Inc.

What they do

Endonovo develops, manufactures, and distributes non-invasive bioelectric medical devices, primarily the SofPulse device, which uses pulsed short-wave radiofrequency at 27.12 MHz for palliative treatment of soft tissue injuries and post-operative pain and edema, and for chronic wounds. The company also has pre-clinical Electroceutical devices targeting chronic kidney disease, NASH, cardiovascular disease, peripheral artery disease, and ischemic stroke. Operations are minimal with revenue declining sharply to near zero.

Revenue drivers

• SofPulse device — The only commercially available product; FDA-cleared, CE Marked, and has CMS National Coverage for chronic wounds; revenue from product sales and related services.
• Pre-clinical pipeline — Devices in development for kidney, liver, cardiovascular, and CNS indications; no current revenue, but potential future income if approved.
• Other historical operations — Includes legacy acquisitions (Aviva, WeHealAnimals) that are not actively pursued; negligible contribution to revenue.

Recent performance

Revenue declined from $135,355 in 2022 to $45,200 in Q2 2023 and just $1,520 in Q3 2023, with Q1 2023 at $87,540. Net income for 2022 was a loss of $18.5 million, and operating cash flow was negative $678,838. The company had zero cash and cash equivalents as of September 30, 2023, with total liabilities of $23.8 million and negative shareholder equity of $23.0 million. Auditors expressed substantial doubt about the company's ability to continue as a going concern.

Strategy

Management's stated direction is to advance its Electroceutical therapy platform through pre-clinical and clinical development, focusing on chronic wounds, inflammatory, and cardiovascular indications. The company also highlights its FDA clearance and CMS coverage for SofPulse as regulatory assets to leverage. However, recent 8-K filings indicate entry into material agreements, possibly for financing or partnerships, though specific terms are not disclosed in the provided excerpts.

Risks

• Going concern risk — Auditors have expressed substantial doubt about the company's ability to continue as a going concern due to ongoing losses and lack of resources.
• Cash and liquidity crisis — Zero cash on hand as of September 30, 2023, with negative equity and high liabilities, severely limiting ability to fund operations.
• Revenue collapse — Quarterly revenue dropped from $121,463 in Q4 2022 to $1,520 in Q3 2023, indicating near-total commercial cessation.
• Thin and volatile stock — Common stock trades on OTCQB with limited volume and sporadic prices, posing risks to capital raising and shareholder value.

Outlook

Management does not provide specific forward-looking guidance beyond its ongoing efforts to develop and commercialize its devices. The company acknowledges risks that actual results may differ materially from its plans. Given the lack of cash and ongoing losses, the immediate outlook is highly uncertain unless additional financing or strategic agreements provide relief.